Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine

The most recent Zaire Ebolavirus (ZEBOV) outbreak was the largest and most widespread in recorded history, emphasizing the need for an effective vaccine. Here, we analyzed human cellular immune responses induced by a single dose of the rVSV-ZEBOV vaccine candidate, which showed significant protective efficacy in endemic populations in Guinea. This is the first in-depth characterization of ZEBOV-GP specific, circulating follicular T cells (cTfh). Since antibody titers correlated with protection in preclinical models of ZEBOV infection, Tfh were predicted to correlate with protection. Indeed, the ZEBOV-specific cTfh data correlated with antibody titers in human vaccines and unexpectedly with the Tfh17 subset. The combination of two cutting edge technologies allowed the immuno-profiling of rare cell populations and may help elucidate correlates of protection for a variety of vaccines.

[1]  E. Deenick,et al.  Human T follicular helper (Tfh) cells and disease , 2014, Immunology and cell biology.

[2]  L. Fernando,et al.  Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. , 2007, The Journal of infectious diseases.

[3]  L. Fernando,et al.  Effective Post-Exposure Treatment of Ebola Infection , 2007, PLoS pathogens.

[4]  D. Zehn,et al.  Antigen affinity and antigen dose exert distinct influences on CD4 T-cell differentiation , 2014, Proceedings of the National Academy of Sciences.

[5]  Alessandro Sette,et al.  Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. , 2013, Immunity.

[6]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[7]  Heinz Feldmann,et al.  The ecology of Ebola virus. , 2007, Trends in microbiology.

[8]  A. Puisieux,et al.  Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus , 2009, Nature Immunology.

[9]  T. Merkel,et al.  Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis , 2015, Clinical and Vaccine Immunology.

[10]  H. Artsob,et al.  Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. , 2011, The Journal of infectious diseases.

[11]  J. Gonzalez,et al.  [Ebola and Marburg hemorrhagic fever viruses: update on filoviruses]. , 2011, Medecine tropicale : revue du Corps de sante colonial.

[12]  H. Ueno,et al.  Human T follicular helper cells: development and subsets. , 2013, Advances in experimental medicine and biology.

[13]  H. Ueno,et al.  Human blood CXCR5(+)CD4(+) T cells are counterparts of T follicular cells and contain specific subsets that differentially support antibody secretion. , 2011, Immunity.

[14]  A. Derbise,et al.  Complete Protection against Pneumonic and Bubonic Plague after a Single Oral Vaccination , 2015, PLoS neglected tropical diseases.

[15]  K. Edwards,et al.  Pertussis vaccines and the challenge of inducing durable immunity. , 2015, Current opinion in immunology.

[16]  Thomas Korn,et al.  Proinflammatory T helper type 17 cells are effective B-cell helpers , 2010, Proceedings of the National Academy of Sciences.

[17]  J. Pawęska,et al.  Ebola virus outbreaks in Africa: past and present. , 2012, The Onderstepoort journal of veterinary research.

[18]  J. Ravetch,et al.  Novel roles for the IgG Fc glycan , 2012, Annals of the New York Academy of Sciences.

[19]  M. Katze,et al.  Antibodies are necessary for rVSV/ZEBOV-GP–mediated protection against lethal Ebola virus challenge in nonhuman primates , 2013, Proceedings of the National Academy of Sciences.

[20]  S. Bertholet,et al.  Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses. , 2014, Vaccine.

[21]  Update: Ebola Virus Disease Epidemic — West Africa, January 2015 , 2015, MMWR. Morbidity and mortality weekly report.

[22]  M. Altfeld,et al.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. , 2016, The New England journal of medicine.

[23]  A. J. Linenthal,et al.  Past and present. , 1987, The Pharos of Alpha Omega Alpha-Honor Medical Society. Alpha Omega Alpha.

[24]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.

[25]  J. Bell,et al.  Vesicular stomatitis virus: re-inventing the bullet. , 2004, Trends in molecular medicine.

[26]  R. Davey,et al.  Emergency postexposure vaccination with vesicular stomatitis virus-vectored Ebola vaccine after needlestick. , 2015, JAMA.

[27]  Petra Bacher,et al.  Flow‐cytometric analysis of rare antigen‐specific T cells , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[28]  Cdc Covid- Response Team.  Update: Ebola Virus Disease Epidemic — West Africa, February 2015 , 2015, MMWR. Morbidity and mortality weekly report.

[29]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[30]  G. Fernando,et al.  Secondary immunisation with high‐dose heterologous peptide leads to CD8 T cell populations with reduced functional avidity , 2007, European journal of immunology.

[31]  S. Khader,et al.  Th17 cytokines and vaccine-induced immunity , 2010, Seminars in Immunopathology.

[32]  V. Engelhard,et al.  Antigen Density Presented By Dendritic Cells In Vivo Differentially Affects the Number and Avidity of Primary, Memory, and Recall CD8+ T Cells 1 , 2003, The Journal of Immunology.

[33]  Heinz Feldmann,et al.  Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses , 2005, Nature Medicine.

[34]  Pawan Kumar,et al.  Th17 cell based vaccines in mucosal immunity. , 2013, Current opinion in immunology.

[35]  N. Sullivan,et al.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule , 2009, Nature Reviews Microbiology.

[36]  W. J. Ramsey,et al.  A Recombinant Vesicular Stomatitis Virus Ebola Vaccine , 2017, The New England journal of medicine.